Company intelligence / Profile preview

Aires Pharmaceuticals, Inc.

San Diego, California, United Statesorpha.net ↗

Ownership: Private
Development stage: Phase 2

Overview

AIR001 showed positive results in a Phase 2a study for HFpEF at Mayo Clinic. A larger multicenter Phase 2 trial was conducted in partnership with Duke University. The program was discontinued for PAH but continued investigation in HFpEF. No commercial products are on the market.

Therapeutic areas: PulmonologyCardiovascularInfectious Diseases
Modalities: Small molecules (notably inhaled sodium nitrite)
Industry: Biotech

Drug pipeline

1 asset

Aironite

Phase 2

Indications: Pulmonary arterial hypertension

Partnerships

Duke University/Duke Clinical Research Institute – clinical trial collaboration on INDIE-HFpEF studyMayo Clinic – site of key clinical studies on AIR001/HFpEF patients

Beyond the preview

Go deeper on Aires Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aires Pharmaceuticals, Inc..

Explore the full profile